# Process for the preparation of beta lactam antibiotics.

## Abstract
The present invention provides a process for the prepa ration of antibacterially active carbapenems of the formula

## Claims
WHAT WE CLAIM IS 1. A process for the preparation of a compound of the formula I EMI36.1 or a salt or ester thereof, wherein R1 and R2 each represent a hydrogen atom or an organic group bonded via a carbon atom to the carbapenem ring, and R3 is a group NR4R5 wherein R4 is an optionally substituted C16 alkyl group or an optionally substituted aryl or heteroaryl group or optionally substituted aryl C16 alkyl or heteroaryl C 1 6 alkyl group and R5 is a hydrogen atom or an optionally substituted C16 alkyl group, or R3 is an optionally substituted aryl or heteroaryl group or an optionally substituted C 1 6 alkyl group which process comprises the reaction of a compound of the formula II or a reactive derivative thereof in which reaction any reactive groups in the groups R and R may be protected, if desired EMI36.2 wherein R and R are as defined in relation to formula I and R is a carboxy blocking group, with an aziridine derivative of the formula III in which any reactive groups in the group R3 may be protected, if desired EMI37.1 wherein R is as defined in relation to formula I and thereafter optionally performing one or more of the following steps i removing any protecting groups in the groups R1, R2 and R3 ii removing any carboxy blocking group iii converting the product into an ester, salt or acid. 2. A process as claimed in claim 1 for the preparation of a compound of the formula IV EMI37.2 or a pharmaceutically acceptable salt or in vivo bydrolysable ester thereof wherein R6 is hydrogen, OH, OS03H or salt or methyl or ethyl ester thereof, and R9 is a group NRlORll wherein R10 is C16 alkyl, phenyl or benzyl andR11 is hydrogen or C16 alkyl, or R is an aryl or heteroaryl group or C1 6 alkyl optionally substituted by aryl, heteroaryl, amino or by a carboxylic acid group or salt or C 4 alkyl ester thereof with the proviso that 6 when P is OS03H or a salt or methyl or ethyl ester thereof the C S and C 6 protons are cis. 3. A process as claimed in either claim 1 or claim 2 wherein C 6 is substituted by an a hydroxyethyl or alsulphonato oxyethy1 group or salt or methyl or ethyl ester thereof. 4. A process as claimed in any of claims 1 to 3 wherein COR3 is acetyl, propionyl, aminoacetyl, benzoyl, furoyl, thenoyl, methylaminocarbonyl or dimethylaminocarbonyl. 5. A process as claimed in claim 1 adapted to the preparation of a compound selected from p Nitrobenzyl SR, 65 3 2 acetamidoethylthio 6 S 1 hydroxyethyl 7 oxo l azabicyclo 3. 2.0 ghept 2 ene 2 carboxylate, p Nitrobenzyl 5R,6S 3 2 thiophen 2 carboxamido ethyl thio 6 S l hydroxyethyl 7 oxo 1 azabicyclo 3.2.O hept 2 ene 2 carboxylate, p Nitrobenzyl 5R,6R 3 2 thiophen 2 carboxamido ethylthio 6 S l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate, Sodium 5R,6R 3 2 thiophen 2 carboxamido ethylthio 6 S l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0uhept 2 ene 2 carboxylate, The sodium salt of p nitrobenzyl SR,6R 3 2 thiophen 2 carboxamido ethylthio 6 S l hydroxysulphonyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate, The disodium salt of 5R,6R 3 2 thiophen 2 carboxamido ethylthio 6 S l hydroxy sulphonyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene2 carboxylic acid, p Nitrobenzyl 5R,6S 3 2 p nitro benzyloxycarbonylamino acetamido ethylthio 6 S 1 hydroxyethyl 7 oxo l azabicyclo 3.2.0 hept 2 ene 2 carboxylate, 5R,6S 3 2 Aminoacetamidoethylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid, p Nitrobenzyl 5R,6R 3 2 p nitro benzylOxycarbonylaminoacetamido ethylthio 6 S l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate, SR,6R 3 2 Aminoacetamidoethylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid and p Nitrobenzyl SR,6S 3 2 dimethyl aminocarbonylaminoethylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate. 6. A process as claimed in any of claims 1 to 4 when performed in the presence of a carbonate or bicarbonate of potassium, calcium, sodium, magnesium or lithium. 7. A compound of the formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, wherein R1 and R2 are as defined in claim 1 and R3 is a group CONR R wherein R4 and R5 are as defined in claim 1. 8. A compound as claimed in claim 7 wherein one of R1 and R2 is a hydrogen atom and the other is a group of the sub formula i CH3CHR6 i wherein R6 is a hydrogen atom or OH, OS03H or salt or methyl or ethyl ester thereof, OR7, SR8, OCO2R7, OCOR8 or OCONHR8 wherein R7 is C14 alkyl, benzyl or nitrobenzyl and R is C14 alkyl, phenyl, benzyl or nitrobenzyl R4 is C1 6 alkyl, phenyl or benzyl, and R5 is hydrogen or C1 6 alkyl. 9. A pharmaceutical composition comprising a compound as claimed in either claim 7 or 8 and a pharmaceutically acceptable carrier. 10. p Nitrobenzyl 5R,6S 3 2 dimethylaminocarbonyl aminoethylthio 6 S l hydroxyethyl 7 oxo l azabicyclo 3.2.0 hept 2 ene 2 carboxylate.

## Description
Process for the preparation of Lactam Antibiotics This invention relates to a novel process for preparing ss lactam antibiotics, in particular carbapenem derivatives. The process also enables certain novel derivatives to be prepared. European Patent Specification No. 0001628 discloses a group of synthetic antibacterial agents containing a 7 oxo 1 azabicyclo 3.2.0 hept 2 ene ring system, i.e. carbapenem derivatives. However all compounds described in that specification were racemic at C S and could only be prepared by a lengthy synthetic sequence. We have now discovered a process for preparing carbapenem derivatives from natural products in relatively few steps and produces carbapenem derivatives as a desirable single optical isomer at C 5. The present invention provides a process for the preparation of compounds of the formula I EMI2.1 and salts and esters thereof, wherein R1 and R2 each represent a hydrogen atom or an organic group bonded via a carbon atom to the carbapenem ring, and R3 is a group NR4R5 wherein R4 is an optionally substituted C1 6 alkyl group or an optionally substituted aryl or heteroaryl group or optionally substituted aryl C16 S alkyl or heteroaryl C1,6 alkyl group and R is a hydrogen atom or an optionally substituted C1 6 alkyl group, or R3 is an optionally substituted aryl or heteroaryl group or an optionally substituted C1,6 alkyl group which process comprises the reaction of a compound of the formula II or a reactive derivative thereof in which reaction any reactive groups in the groups R1 andR2 may be protected, if desired EMI2.2 wherein R and R are as defined in relation to formula I and PX is a carboxy blocking group, with an aziridine derivative of the formula III in which any reactive groups in the group R3 may be protected, if desired EMI3.1 3 wherein R is as defined in relation to formula I and thereafter optionally performing one or more of the following steps i removing any protecting groups in the groups R1, Rand R ii removing any carboxy blocking group iii converting the product into an ester, salt or acid. Preferably in the compounds of the formula I either R or P is a hydrogen atom. In an alternative aspect both R1 and R2 are hydrogen atoms. 2 When the group R1 or P represents an organic group, it may be selected from C1 10 alkyl, C2 10 alkenyl, C2 10 alkynyl, C3 7 cycloalkyl C1,6 alkyl,C3 7 cycloalkyl, aryl, aryl C1,6 alkyl, heterocyclyl, heterocyclyl C1,6 alkyl, heteroaryl and heteroaryl C1,6 alkyl, any of the above groups being optionally substituted. Suitably the hetero atom or hetero atoms in the above named heteroaryl and or heterocyclyl moieties is are selected from 1 to.4 oxygen, nitrogen or sulphur atoms.Suitable optional substituents include C1 6 alkyl, amino, C1 6 alkanoylamino, mono , di and tri C1 6 alkylamino, hydroxy, C1 6 alkoxy, mercapto, C1 6 alkylthjo, heteroarylthio, arylthio, sulphamoyl, carbamoyl, amidino, guanidino, nitro, chloro, bromo, fluoro, carboxy and salts and esters thereof, C1,6 alkanoyloxy, arylcarbonyl and heteroarylcarbonyl. More suitably one of R1 and R2 is a hydrogen atom and the other is selected from a group of the sub formula i CH3CHR6 i wherein R6 is a hydrogen atom or a group selected fromOH, OS03H or salt or methyl or ethyl ester thereof, OR7SR8, OC02R , OCOR8 or OCONHR8 wherein R7 is C14 alkyl, benzyl or nitrobenzyl and R8 is C14 alkyl, phenyl, benzyl or nitrobenzyl. Also suitably one of R and R is a hydrogen atom and the other is a hydroxypropyl or a sulphonato oxypropyl or a salt or ester thereof. Favoured values of R 6 include a hydroxy group and a OS03H group or salt or methyl or ethyl ester thereof.Compounds of the formula I containing a sulphate group on the C 6 side chain are normally provided in the form of a pharmaceutically acceptable salt of that group. Suitably R is a groupNR4R5 as hereinbefore defined. Suitably R is an optionally substituted aryl or heteroaryl group or an optionally substituted C1 6 alkyl group. Suitable substituents for R, R4 and R5 include those described as suitable for R and R More suitably R is C16 alkyl or a phenyl or benzyl group and R is a hydrogen atom or a C16 alkyl 3 group. More suitably also R is an aryl or heteroaryl group or C16 alkyl or C16 alkyl substituted by an aryl or heteroaryl group or an amino group or by a carboxylic acid group or salt or ester thereof. Favoured values for R4 include the methyl, ethyl, phenyl and benzyl groups. Favoured values for R include the hydrogen atom and methyl and ethyl groups. Thus particularly favoured values for the group CONR4R5 include methylaminocarbonyl, dimethylaminocarbonyl, ethylaminocarbonyl, phenylaminocarbonyl and benzylaminocarbonyl. When R is an aryl or heteroaryl group convenient vases for R include phenyl, furyl, pyrrolyl, thienyl, quinolyl, naphthyl, indolyl, benzofuryl, thionaphthyl, and such groups substituted by an alkyl group of 1 to 4 carbon atoms. Suitably is an alkyl group of 1 to 6 carbon atoms optionally substituted by an aryl group or an amino group or by a carboxylic acid group or salt or C1,4 alkyl ester thereof for example more suitable values for R3 include methyl, ethyl, propyl, butyl, benzyl, phenethyl, aminomethyl, aminoethyl, carboxymethyl or a salt or C 1 4 alkyl ester thereof and carboxyethyl or a salt or C14 alkyl ester thereof. Preferred values for COR3 therefore include the acetyl, propionyl, aminoacetyl, benzoyl, furoyl, thenoyl, methylaminocarbonyl and dimethylaminocarbonyl groups, of these the aminoacetyl group is particularly preferred. The major utility of the compounds prepared by the process of this invention is as pharmaceuticals and accordingly the salts and esters of the compounds of the formula I are preferably pharmaceutically acceptable.The compounds of this invention both pharmaceutically acceptable and non pharmaceutically acceptable may be used as intermediates and also as antibacterial agents or P lactamase inhibitors in non pharmaceutical usage such as a disinfectant or paint additive. In a favoured aspect of this invention there is provided a process for the preparation of a class of compounds of the formula IV EMI6.1 and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof wherein R is as hereinbefore defined, and R9 is a group NR 10R11 wherein P 10 is C16 alkyl, phenyl or benzyl and Rll is hydrogen or C16 9 alkyl, or R is an aryl or heteroaxyl group or C1 6 alkyl optionally substituted by aryl, heteroaryl, amino or by a carboxylic acid group or salt or C 1 4 alkyl ester thereof. Preferably in the compounds of the formula IV when P6 is OS03H or salt or methyl or ethyl ester thereof the C S and C 6 protons are cis. Particularly apt compounds of the formula IV are those of the formula V EMI7.1 and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof wherein R12 is an aryl or heteroaryl group or an alkyl group of 1 to 6 carbon atoms optionally substituted by an aryl or heteroaryl group or an amino group or by a carboxylic acid group or salt or C1 4 alkyl ester thereof, and R13 is a hydrogen atom or a pharmaceutically acceptable salt or a S03H group. Further particularly apt compounds of the formula IV are those of the formula VI EMI8.1 and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof wherein R3 is as defined in relation to formula I and R14 is a hydrogen atom or a SR8 group wherein R8 is as defined hereinbefore. The compounds of the formula I wherein one of R1 or R2 is hydrogen and the other is not may be in the form of cis or trans isomers about the p lactam ring, that is to say they may have the 5R, 6R or 5R, 6S configuration, or they may be provided as mixtures of such isomers although this is not normally preferred.Furthermore certain compounds of the formulae 1 for example those of formula IV may have R or S stereochemistry at C 8 except of course when R6 is a hydrogen atom or may be in the form of mixtures thereof. The compounds of the formula V wherein R 13 is a group S03H or a pharmaceutically acceptable salt thereof, are preferably in the 5R, 6R, 8S configuration as the intermediates are more readily available. Preferred compounds which may be produced by the process of this invention include Sodium 5Rw6R 3 L2 thiophen 2 carboxamido ethylthio 6 s lhydroxyethyl 7oxo l azabicyclo 3.2.O hept 2 ene 2carboxylate, The sodium salt of p Nitrobenzyl 5R,6R 3 2 thiophen 2 carboxamido ethylthio 6 S l hydroxysulphonyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylatea The disodium salt of 5R,6R 3 2 thiophen 2 carboxamido ethylthio 6 S l hydroxy sulphonyloxyethyl 7 oxo l azabicyclo 3.2. 0 hept 2 ene 2 carboxylic acid, SR, 6S 3 2 Aminoacetamidoethylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0. hept 2 ene 2 carboxylic acid, 5R,6R 3 2 Aminoacetamidoethylthio 6 S l hydroxyethyl 7 oxo l azabicyclo 3.2,0hept 2 ene 2 carboxylic acid, Suitably the compounds of the formula I are in the form of a pharmaceutically acceptable salt, for example those of the alkali and alkaline earth metals such as the sodium, potassium, magnesium, calcium and ammonium salts. Of these the sodium and potassium salts are preferred. It is to be realised that if a free alkylamino group CH2 NH2 is present in the group R3 then a zwitterion of the compound of the formula I may be formed, said zwitterion normally being formed with the carboxylic acid function at the C 2 position. If a carboxylic acid group is present in the group R3 then optionally this may be salified by a pharmaceutically acceptable salt as hereinbefore described. Suitable esters of the compounds of the formula I include those cleavable by biological methods such as enzy matic hydrolysis, in vivo hydrolysis, and those cleavable by chemical methods such as hydrogenolysis, hydrolysis, electrolysis or photolysis. Suitably the carboxylic acid is esterified by a group of the sub formula a , b , c , d , e or f EMI10.1 wherein A1 is a hydrogen atom, C C1 6 alkanoyl or an C 1 5 alkyl group optionally substituted by C1 7 alkoxy or C1,7 carboxylic acyloxy, or an alkenyl or alkynyl group of up to 5 carbon atoms A is a hydrogen atom or a methyl group A3 is a phenyl group or a phenyl group substituted by a fluorine, chlorine or bromine atom or a nitro, C1 3 alkyl or C1 3 alkoxy group A4 is a hydrogen atom or a pheyl group or phenyl group substituted by a fluorine, chlorine or bromine atom or a nitro, C1 3 alkyl or C1 3 alkoxy group A5 is a hydrogen atom or a methyl group A is a C1 6 alkyl, phenyl, phenoxy, phenyl C1 3 alkyl, phenyl C1 3 alkoxy or C1 4 alkoxy group or A5 is joined to A6 to form a phthalidyl, dimethylphthalidyl or dimethoxyphthalidyl group A7 is a C1 4 alkyl, phenyl, chlorophenyl or nitrophenyl group A is a C1 4 alkyl or phenyl group 10A9 is a C14 alkyl or phenyl group A is C1 4 alkyl and A is a C1 4 alkyl or CHA1A2 is a phenacyl or bromophenacyl group. Favourably A1 is a hydrogen atom or a methyl, ethyl, vinyl or ethenyl group. Favourably A2 is a hydrogen atom. Favourably A3 is a phenyl, p bromophenyl, p methoxyphenyl or p nitrophenyl group. Favourably A4 is a hydrogen atom. Favourably A6 is a methyl, t butyl or ethoxy group or is joined to A5. Favourably A7 is a methyl group. Favourably A5 is a hydrogen atom. Preferred groups of the sub formula a include the methyl, ethyl and acetonyl groups. Preferred groups of the sub formula b include the benzyl and p nitrobenzyl groups. When A5 is hydrogen, suitably A6 is selected from methyl, ethyl, n propyl, isopropyl, n butyl, tert butyl, phenyl, benzyl, methoxy, ethoxy, n propyloxy and isopropyloxy. Preferably A6 is tert butyl. Preferred groups of the sub formula c include the acetoxymethyl, pivaloyloxymethyl, ethoxycarbonyloxymethyl, phthalidyl, a ethoxycarbonyloxyethyl and a acetoxyethyl groups.These esterifying groups are favoured as they tend to form in vivo hydrolysable esters. A preferred group of the sub formula d is the methoxymethyl group. Preferred groups of the sub formula e include the trimethylsilyl, tert butyldimethylsilyl and tertbutyldiphenylsilyl groups. A preferred group of the sub formula f is p methoxycarbonylbenzyl. Particularly preferred esterifying groups are the p nitrobenzyl and phthalidyl groups. Pharmaceutically acceptable in vivo hydrolysable esters are those esters which hydrolyse in the human body to produce the parent acid or its salt. Such esters may be identified by administration to a test animal such as a rat or mouse by intravenous administration and thereafter exaining the test animal s body fluids for the presence of the compound of the formula I or salt. Suitable esters of this type include those of sub formula c as hereinbefore defined. Further suitable esters include di Cl 6 alkylamino C1 6 alkyl esters such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl and diethylaminoethyl. Compounds of the formula I in the form of chemically cleavable esters are also of value as intermediates. Such chemically cleavable esters are preferably formed at the carboxylic acid function at theC 2 position. Suitably the esters of use as intermediates are those cleavable by catalytic hydrogenation, for example a benzyl ester optionally substituted by C13 alkoxy, C13 alkanoyloxy, halogen or a nitro group. Of these the p nitrobenzyl ester is preferred. During the process of this invention, any reactive groups in the groups R1, R2 and R3 may be protected. For example if R3 contains an amino group it may be protected by a protected amino group such as those known in the art, for example enamino groups, or p nitrobenzyloxycarbonylamino which on hydrogenation affords an amino group. Any carbonyl group in R3 may be esterified which on hydrogenation affords a carboxylic acid or salt thereof. It must be realised that salts of the compounds of the formulae I formed with pharmaceutically unacceptable ions are useful as they may serve as intermediates in the preparation of pharmaceutically acceptable salts by ion exchange, or they may be useful as intermediates in the preparation of in vivo hydrolysable esters. An example of such a salt is the lithium salt, which may be converted into other salts such as the sodium, potassium, calcium or magnesium salt by ion exchange. Suitably R in the compound of the formula II is an ester, suitably a cleavable ester or an in vivo hydrolysable ester. Suitably cleavable esters of the formula II for use in such a process are those that are cleavable by chemical methods. Apt esters include those cleavable by hydrogenation, for example a benzyl ester optionally substituted by Cl,g alkoxy, C1,3 alkanoyloxy, halogen or a nitro group. Of these the p nitrobenzyl ester is preferred. Other apt esters for use in this process are in vivo hydrolysable esters as hereinbefore described. The reaction of an ester of a compound of the formula II with the aziridine derivative normally takes place in an inert organic solvent such as dimethyl formamide, dichloromethane or chloroform. The reaction is normally carried out at a non extreme temperature for example 300C to 500C, preferably OOC to 300C, and most conveniently at ambient temperature. The reaction is normally conducted in the presence of a base such as potassium, calcium, sodium, magnesium and lithium, carbonate or bicarbonate, preferably such bases being in an anhydrous form. Organic bases may be suitable also, for example triethylamine. Suitable methods of hydrogenolysis for the preparation of compounds of the formula I include hydrogenation in the presence of a transition metal catalyst. The pressure of hydrogen used in the hydrogenation step may be low, medium or high, but in general an approximately atmospheric or slightly superatmospheric pressure is preferred. The transition metal catalyst employed is preferably palladium for example palladium on charcoal, palladium on barium sulphate or palladium on calcium carbonate. The hydrogenation may be effected in any convenient solvent in which the compound is soluble such as tetrahydrofuran, dioxan, ethanol, or such solvents in mixture with water.Phosphate buffer may also be included in the hydrogenation medium, this is particularly advantageous if it is desired to produce the compound of the formula I in the form of a zwitterion. If the hydrogenation is carried out in the presence of a base then a salt of a compound of the formula I is produced. Suitable bases include sodium bicarbonate, sodium carbonate, potassium carbonate, calcium carbonate and lithium carbonate. If no base is present then hydrogenation leads to the preparation of an acid of a compound of the formula I which may then may be neutralised if desired to yield a salt, such neutralisation being effected in conventional manner. Re esterification of a carboxyl group of a salt of a compound of the formula I may be effected in conventional manner. Suitable methods include the reaction of an alkali metal salt of the compound of the formula I such as the sodium or potassium salt with a reactive halide or sulphonate ester such as a bromide, chloride, mesylate or tosylate. Such esterification may be carried out under conventional conditions for example in dimethylformamide at room temperature. Comppunds of the formula II may be prepared by the reaction of N bromoacetamide with a corresponding compound of the formula VII EMI17.1 wherein R1, R2 and Rx are as defined in relation to formula II . The reaction of the ester of the compound of the formula VII with N bromoacetamide is most suitably carried out at a temperature such as 15 l50C to 250C in a solvent such as moist acetone or dioxan. The desired product may be obtained by diluting with chloroform, washing with water and evaporating the dried organic layer. The compounds of the formula VII and esters thereof may be obtainable directly from natural sources, or may be prepared by the modification of natural products. For example they may be prepared by the methods disclosed in UK Patent Specification Number 1489235, European Patent Application PublicationNumbers 0004132, 0005349, 0007152 and 0005348,United States Serial Numbers 014,995 and 025,556 andJapanese Application Numbers 25014 79, 56215 79, 50233 79 and 56214 79, European Patent Application PublicationNumbers 0001627 and 0001628 and OLS 2724560. The groups R1 and R2 may be modified by such methods as are known for the modification of the C 6 substituent of known carbapenem derivatives. This may be performed after the formation of the S CH2 CH2 NHCOR side chain at the C 3 postion. Certain compounds produced by the process of this invention are novel. Accordingly in a further aspect this invention provides a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, wherein R1 and R2 are as defined with respect to formula I , and R3 is a group of formula 45 4 and 5 NR R wherein R and R are as defined with respect to formula I . The present invention also provides a pharmaceutical composition which comprises a compound of the formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein R1 and R2 are as defined hereinbefore and R3 is a group NR4R5 wherein R4 and R5 are as defined hereinbefore, and a pharmaceutically acceptable carrier. Particularly suitable salts for use in such compositions include the sodium and potassium salts. The compositions of this invention may be prepared by the conventional methods of preparation of antibiotic compositions and may be adapted for oral, topical or parenteral administration in conventional manner. Aptly the compositions of this invention are in the form of a unit dose composition adapted for oral administration. Alternatively the compositions of this invention are in the form of a unit dose composition adapted for administration by injection. Unit dose forms according to this invention will normally contain from 50 to 500 mgs of a compound of this invention, for example about 62.5, 100, 125, 150, 200, 250 or 300 mgs. Such compositions may be administered from 1 to 6 times a day or more conveniently 2, 3 or 4 times a day so that the total daily dose for a 70 kg adult is about 200 to 2000 mg, for example about 400, 600, 750, 1000 or 1500 mg. The compositions of this invention may be used to treat infections of the respiratory tract, urinary tract or soft tissues in humans, or may be used to treat mastitis in cattle. The carriers used in the compositions of this invention may include diluents, binders, disintegrants, lubricants, colours, flavouring agents and preservatives in conventional manner. Thus suitable agents include lactose, starch, sucrose, calcium phosphate, sorbitol, polyvinylpyrrolidone, acacia, gelatin, tragacanth, .potatp starch, polyvinylpolypyrrolidone, magnesium stearate and sodium lauryl sulphate. Orally administrable forms of the compositions of this invention are most suitably in the form of unitdose units such as tablets or capsules. In addition to being antibacterial agents in their own right the compounds of this invention are also able to enhance the effectiveness of penicillins and cephalosporins against ss lactamase producing strains of gram positive and gram negative bacteria presumably by virtue of being P lactamase inhibitors. The present invention also provides a synergistic pharmaceutical compostion which comprises a pharmaceutical composition as hereinbefore described which also contains a penicillin or a cephalosporin. Suitable penicillins for inclusion in the compositions of this invention include benzyl penicillin, phenoxymethylpenicillin, ampicillin or a pro drug therefor, amoxycillin or a pro drug therefor, carbenicillin or a pro drug therefor, ticarcillin or a pro drug therefor, suncillin, sulbenicillin, azlocillin and mezlocillin. Particularly suitable penicillins for inclusion in orally administrable compositions of this invention include ampicillin and its orally administrable prodrugs, amoxycillin and its orally administrable prodrugs and orally administrable pro drugs of carbenicillin.Thus particularly suitable penicillins include ampicillin anhydrate, ampicillin trihydrate, sodium ampicillin, talampicillin hydrochloride, pivampicillin hydrochloride, bacampicillin hydrochloride, amoxycillin trihydrate, sodium amoxycillin and the sodium salts of the phenyl and 5 indanyl a esters of carbenicillin. A preferred penicillin for inclusion in the orally administrable compositions of this invention is alkoxy cillin trihydrate. A further preferred penicillin for inclusion in the orally administrable compositions of this invention is ampicillin trihydrate. Particularly suitable penicillins for inclusion in injectably administrable compostions of this invention include injectable salts such as the sodium salts of ampicillin, amoxycillin, carbenicillin and ticarcillin. A preferred penicillin for inclusion in the injectably administrable compositions of this invention is sodium amoxycillin. A further preferred penicillin for inclusion in the injectably administrable compositions of this invention is sodium ampicillin. Particularly suitable cephalosporins for inclusion in the compositions of this invention include cephaloridine, cephalexin, cephradine, cefazolin and cephalothin. A particularly suitable cephalosporin for inclusion in the orally administrable compositions of this invention is cephalexin. Particularly suitable cephalosporins for inclusion in the injectably administrable compositions of this invention include cefazolin and cephradine, generally as a pharmaceutically acceptable salt such as the sodium salt. The weight ratio between a compound of this invention and a penicillin or cephalosporin is generally from 10 1 to 1 10, more usually from 5 1 to 1 5 and normally 3 1 to 1 3. The penicillin or cephalosporin is generally utilised in its conventionally administered amount. The following Examples serve to illustrate the invention. Example 1 p Nitrobenzyl 5R,6S 3 2 acetamidoethvlthio 6 S l hydroxYethyl 7 oxo l azabicyclor3.2.olhept 2 ene 2 carboxylate.EMI22.1 Step A A solution of the ester el 350 mg in a mixture of dioxan 7 ml and water 1 ml was stirred withN bromoacetamide 108 mg at ambient temperature for 4.5 min. Chloroform 30 ml was then added and the solution was washed with pH7 phosphate buffer 0.05M, 30 ml and brine 30 ml . Evaporation of the dried MgS04 organic layer afforded a foamy product which contained the thiol e2 .Step B Half of the product from step A was dissolved inDMF 1 ml and stirred with anhydrous K2C03 11 mg for 20 min at room temperature in the presence ofN acetylaziridine 0.2 ml . Ethyl acetate 30 ml was added and the organic solution was washed with water 4 x 30 ml and brine 30 ml . The organic layer was dried MgS04 and concentrated in vacuo to afford a crude product which was chromatographed on silica gel using a gradient elution of chloroform to 25 ethanol in chloroform. The major product was the title compound e3 20 mg . Example 2 p Nitrobenzyl 5R, 6S 3 2 thiophen 2 carboxamido ethylthio 6 S l hYdroxyethyl Oxo l azabicyclo 3.2.0 hept 2 ene 2 carboxylateEMI24.1 Step A The ester el 250 mg was converted into the thiol e2 by the method described in Example 1, step A.Step B The product from step A was dissolved in DMF 2 ml and the solution was treated with potassium carbonate 14 mg and N ethylenethiophen 2 carboxamide 167 mg with stirring at room temperature. After 20 min, ethyl acetate 30 ml was added and the solution was washed with water 3 x 30 ml and brine 30 ml . The organic phase was dried MgSO4 and concentrated in vacuo to yield a product which was chromatographed on silica gel using a gradient elution from 20 petroleum ether in ethyl acetate to 10 ethanol in ethyl acetate.The requisite fractions were collected and evaporated in vacuo to afford the title compound e4 127 mg A max EtOH 319 12,759 and 266 18,350 nm v max KBr 1770, 1695 and 1630 cm 1 6 DMF d7 1.27 3H, d, J 6 Hz, CH3CH , 3.0 3.7 7H, m, 4 CH2, SCH2CH2N and 6 CH , ca 4.0 4.4 2H, m, 5 CH and CHCH3 , 5.13 1H, d, J 5 Hz,OH , 5.28 and 5.56 each 1H, d, J 14 Hz, CH2Ar , 7.14 1H, dd, J 3.5 and 5Hz, thiophen 3 CH , 7.8 4H, m, 2 x thiophen CR and 2 x Ar , 8.25 2H, m, 2 x Ar , and 8.81 lH, br, NH . Example 3 p Nitrobenzyl SR, 6R 3 2 thiophen 2 carboxamido ethylthio 6 r l hydroxyethyl 7 oxo l azabic yclo 3.2.0. hept 2 ene 2 carboxylate EMI25.1 Step A The ester e5 400 mg was converted to the thiol e6 with N bromoacetamide 123 mg in the manner described in Example 1, step A.Step B The product from step A was treated with 1 2thenoyl aziridine 267 mg and potassium carbonate 22 mg exactly as described in Example 2, step B. The title compound e7 was obtained as a foam 172 mg A max EtOH 318 and 266 nm v max CH2C12 3600, 3450, 1780, l 1705 and 1650 cm b DMF d7 1.30 3H, d, J 6Hz, CH3 CH , 3.10 3.75 7H, m, 4 CH2,SCH2CH2N and 6 CH , 3.95 4.45 2H, m, 5 CH and C CH3 , 5.07 1H, d, J 5.5 Hz, OH , 5.31 and 5.66 each 1H, d, J 14 Hz, CH2Ar , 7.13 1H, dd, J 3.5 and 5Hz, thiophen eCH , 7.80 4H, m, 2 x thiophen CH and 2 x Ar , 8.26 2H, d, J 9 Hz, 2 x Ar and 8.82 1H, br, NH . Example 4Sodium 5Rs6R 3 2 thioPhen 2 carboxamido ethylthiol 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate EMI27.1 A solution of the ester e7 120 mg in 30 aqueous dioxan 10 ml was shaken with hydrogen over 5 Pd on C catalyst 150 mg which had been prehydrogenated in aqueous dioxan 5 ml for O.Sh. After 3.25h the mixture was filtered over Celite washing with water 30 ml and the filtrate was then concentrated in vacuo to a volume of ca 20 ml. The aqueous solution was washed with ethyl acetate 3 x 30 ml and then further concentrated to ca 3 ml before loading onto a column 20 x 2.5 cm of Biogel P2. Elution with water gave fractions containing the title compound e8 .These were combined and freezedried to afford the product as an amorphous solid 40 mg A max H20 300 sh, 275 and 255 nm. 9 max KBr 1750 and 1640 1590 cm Example 5The sodium salt of p Nitrobenzyl 5R, 6R 3 2 thiophen 2 carboxamido ethylthio 6 S 1 hydroxysulphonyloxyethyl 7 oxo l azabicvclo 3.2.0 hept 2 ene 2 carboxylateEMI28.1 Step A A solution of the monoester, mono sodium salt e9 2.26 g in water 50 ml was thoroughly shaken with a solution of cetylbenzyldimethylammonium chloride 1.54 g in dichloromethane 50 ml . The organic layer was separated, dried MgS04 and evaporated in vacuo to afford a foam.This product was dissolved in a mixture of dioxan 20 ml and water 3 ml and the solution was then treated with N bromoacetamide 482 mg with stirring at room temperature for 4.5 min. Chloroform 60 ml was added and the solution was washed with water 30 ml and brine 30 ml . Evaporation of the dried MgSO4 organic layer furnished a foamy product which contained the thiol elO .Step B The product from step A was dissolved in DMF 12 ml .and the solution was stirred with l 2 thenoylaziridine 1.0 g and anhydrous potassium carbonate 100 mg for 25 min. Ethyl acetate 100 ml was added and the solution was washed with water 3 x 70 ml and brine 50 ml . The organic phase was then dried MgSO 4 and concentrated in vacuo. The product was chromatographed on silica gel using a gradient elution of CHCl3 to 20 EtOH in CHC13. The quaternaryammonium salt ell was obtained as a foam 1.26 g A max EtOH 317 and 265 nm v max CH2C12 1780, 1705 and 1645 cm Step C A solution of ell 1.26g in acetone 8 ml and a solution of sodium iodide 198 mg in acetone 3 ml were mixed together. The white precipitate formed was filtered off washing well with acetone and ether, and then dried to give a solid 578 mg which consisted of the title compound e12 A max H20 314 10,911 and l 270 16,757 M max KBr 1765, 1690 and 1630 cm 6 DMF d7 1.48 3H, d, J 6 Hz, CH3CH , ca 3.0 4.0 7H, m, 4 CH2, SCH2CH2N and 6 CH , 4.15 4.80 2H, m, 5 CH and CH3CH , 5.31 and 5.54 each 1H, d, J 14 Hz,CH2Ar , 7.14 1H, dd, J 3.5 and 5 Hz, thiophen ss CH , 7.70 7.95 4H, m, 2 x thiophen CH and 2 x Ar , 8.27 2H, d, J 8.5 Hz, 2 x Ar and 8.83 1H, br, NH . Example 6The disodium salt of 5R,6R 3 2 thiophen 2 carbox amido ethylthio 6 S 1 hydroxysulphonyloxyethyl 7 oxo l azabicvclo 3.2.0 hept 2 ene 2 carboxylic acidEMI30.1 A mixture of 5 Pd on C 150 mg and 30 aqueous dioxan lOml was shaken under an atmosphere of hydrogen for 0.5 h. A solution of the ester e12 105 mg in 30 aqueous dioxan 2 ml was added to the mixture and hydrogenation was continued for a further 3.25 h. Work up and chromatography on Biogel P2 as described inExample 4 afforded fractions containing the title compound el3 .These were combined and freeze dried to give the product as a solid 33 mg A max H20 298 sh and 273 l nm max KBr 1755 and 1625 br cm Example 7 p Nitrobenzvl 5R, 6S 3 2 p nitrobenzyloxycarbonylamino acetamido ethylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylateEMI31.1 Step A The ester el 500 mg was treated with N bromoacetamide 154 mg as described in Example 1, step A, to afford the thiol e2 .Step B The thiol e2 was treated with l p nitrobenzyloxycarbonylaminoacetyl aziridine 312 mg in the manner described in Example 2, step B. Chromatography on silica gel using a gradient elution of CHC13 to 25 EtOH CHCl3 3 gave the title compound e14 as a yellow solid 107 mg A max EtOH 315 and 265 nm. 9 max KBr 1770, 1700 and 1 1675 sh cm Example 8 SR,6S 3 2 Aminoacetamidoethvlthio 6 S l hvdroXvethyl 7 oxo l azabicvclor3.2.01hePt 2 ene 2 carboxylic acidEMI32.1 A mixture of the ester el4 80 mg , 5 Pd on C 120 mg , dioxan 7 ml and 0.05 M pH 7 phosphate buffer 3 ml was shaken under an atmosphere of hydrogen for 2h.The mixture was filtered through Celite, washing with water and then concentrated to a volume of ca 20 ml.The aqueous solution was washed with ethyl acetate 5 x 30 ml and further concentrated in vacuo to 17 ml to afford an aqueous solution of the title compound el5 23 mg A portion of the solution was freezedried to give a solid A max H20 298 nm v max KBr l 1750, 1665 and 1600 br cm Example 9 p Nitrobenzyl 5R,6R 3 2 p nitrobenzyloxycarbonyl aminoacetamidoethylthio 6 S l hvdroxvethvl 7 oxo l azabicyclo 3.2.0 hept 2 ene 2 carboxylateEMI33.1 Employing the methodology of Example 7, the ester e5 500 mg was converted into the title compound e16 140 mg A max EtOH 314 13000 and 266 20,520 nm max CH2Cl2 3430, 1780, 1730 and 1695 cm 1. Example 10 5R,6R 3 2 Aminoacetamidoethylthio 6 S 1 hydroxy ethvl 7 oxo 1 azabicvclor3.2.01hept 2 Ã©ne 2 carboxylic acidEMI34.1 Using the procedure of Example 8, the ester e16 55 mg was hydrogenolysed to the title compound e 17 13 mg A max H20 298 nm. Example 11 p Nitrobenzvl 5R,6S 3 2 dimethylaminocarbonylaminoethylthio 6 S l hydroxyethyl 7 oxo l azabicycl 3.2.0 hept 2 ene 2carboxylateEMI35.1 Step A The ester el 500 mg was converted into the thiol e2 by the method of Example 1, step A. Step B The thiol e2 was treated with N dimethylcarbamoyl aziridine 255 mg and K2C03 30 mg as described in Example 1, step B. Chromatography of the product using CHCl3 to 20 EtOH CHC13 to elute afforded the title compound el8 as a white solid 53 mg A max. EtOH 319 11,275 and 265 10,629 nm. v max. KBr 1770, 1695 and 1630 cm 1 6 DMF d7 1.27 3H, d,J 6Hz, CH3CH , 2.82 6H, s, Me2N , ca. 2.9 3.6 7H, m, 4 CH2, CH2CH2S and 6 CH , 3.95 4.35 2H, m, 5 CH andCH3CH , 5.1 1H, br, OH , 5.29 and 5.56 each 1H, d, J 14Hz, ArCH2 , 6.63 1H, br, NH and 7.80 and 8.24 each 2H, d, J 9Hz, ArCH2 .